Urosepsis

Topic Overview

Summary

Urosepsis is life-threatening organ dysfunction resulting from a dysregulated host response to urinary tract infection. It represents 20-30% of all sepsis cases and carries mortality rates of 20-40% in septic shock despite treatment. [1,2] The condition demands recognition of the "surgical sepsis" principle: infected obstructed urinary systems require urgent drainage in addition to antimicrobials. [3] Delayed source control in obstructive uropathy is associated with multi-organ failure and death. Management follows the Surviving Sepsis Campaign bundle with specific focus on early empirical broad-spectrum antibiotics and emergency decompression of obstructed systems. [4,5]

Key Facts

• Definition: Sepsis (life-threatening organ dysfunction) arising from urinary tract source [1]
• Incidence: Most common source of community-acquired sepsis in patients >65 years [2]
• Mortality: 10-15% overall; 20-40% with septic shock; 60% if source control delayed >24 hours [3,6]
• Critical principle: Antibiotics alone CANNOT treat infected obstructed systems—drainage is mandatory [3,7]
• Common organisms: E. coli 50-70%, Klebsiella 10-15%, Enterococcus 5-10%, with increasing ESBL prevalence [8,9]
• Time-critical intervention: Each hour delay in antibiotics increases mortality by 7-8% [10]

Clinical Pearls

Infected + Obstructed = Surgical Emergency
An obstructed urinary system with infection requires drainage within 6 hours. Antibiotics cannot penetrate an obstructed system under pressure. [3,7]

Renal stone + Fever = Urosepsis until proven otherwise
This combination mandates urgent imaging (CT KUB), blood cultures, and empirical IV antibiotics while arranging emergency decompression. [11]

Catheter-associated UTI is the most preventable cause
75% of healthcare-associated UTIs are catheter-related. Daily assessment of catheter necessity reduces CAUTI rates by 50%. [12,13]

Hypotension with pyelonephritis = ICU involvement
Urosepsis with shock has 40% mortality. Early ICU referral, aggressive resuscitation, and vasopressor support improve outcomes. [6,14]

Why This Matters Clinically

Urosepsis sits at the intersection of emergency medicine, urology, infectious diseases, and critical care. Early recognition prevents progression to multi-organ failure. The condition exemplifies the "golden hour" principle: bundled interventions (cultures, antibiotics, fluids, source control) within 60 minutes reduce mortality by 50%. [4,5,10] In obstructive uropathy, source control (nephrostomy or stent) is as critical as antibiotics—this is a "surgical sepsis" requiring procedural intervention. [3,7]

---

Visual Summary

Visual assets to be added:

• Urosepsis pathophysiology diagram (ascending infection → bacteremia → SIRS → organ dysfunction)
• CT demonstrating infected hydronephrosis with obstructing stone
• Sepsis Six bundle infographic (within 1 hour interventions)
• Source control decision algorithm (nephrostomy vs retrograde stent)
• E. coli virulence factors and urothelial invasion
• Timeline: Time to antibiotics vs mortality curve
• Red flag recognition flowchart

---

Epidemiology

Incidence and Prevalence

Urosepsis accounts for 20-30% of all sepsis cases, making it the most common source after respiratory tract infections. [1,2] In patients over 65 years, urinary tract sources predominate, representing 35-40% of community-acquired sepsis admissions. [2,15] Annual incidence is estimated at 40-50 cases per 100,000 population, with rising trends due to aging populations, increasing antibiotic resistance, and more frequent urological instrumentation. [16]

Demographics

Age Distribution

• Median age: 70-75 years [2]
• Elderly (>65 years): 60-70% of cases [15]
• Increased incidence with age due to:
  • Benign prostatic hyperplasia (men)
  • Urogenital prolapse (women)
  • Functional/cognitive impairment with incomplete bladder emptying
  • Higher rates of catheterization

Sex Distribution

• Women: Higher overall UTI incidence (shorter urethra, proximity to rectum)
• Men >50 years: Higher urosepsis mortality (prostatic obstruction, complicated UTI) [17]
• Pregnancy: 20-30-fold increased risk of progression from asymptomatic bacteriuria to pyelonephritis [18]

Geographic and Temporal Variation

Incidence shows seasonal variation with 15-20% increase in summer months, potentially related to dehydration and concentrated urine facilitating bacterial growth. [19] Healthcare-associated urosepsis (predominantly catheter-related) shows no seasonal pattern.

Risk Factors

High-Risk Conditions

Iatrogenic Factors

• Urethral catheterization (75% of nosocomial UTIs) [12]
• Ureteric stents (chronic bacterial colonization)
• Nephrostomy tubes
• Recent cystoscopy, ureteroscopy, or transurethral resection
• Prostate biopsy (3-5% sepsis risk) [27]

Structural Urological Abnormalities

• Vesicoureteric reflux
• Posterior urethral valves
• Ureterocele
• Polycystic kidney disease
• Ileal conduit/urinary diversion

---

Pathophysiology

Molecular Mechanisms

Stage 1: Bacterial Colonization and Invasion

Uropathogenic E. coli (UPEC) accounts for 50-70% of cases and possesses specific virulence factors: [8,28]

1. Adhesion: Type 1 fimbriae (FimH) bind mannose residues on urothelial cells
2. Invasion: UPEC triggers endocytosis, forming intracellular bacterial communities (IBCs)
3. Immune evasion: Capsular polysaccharides inhibit phagocytosis and complement
4. Tissue damage: Hemolysin (HlyA) causes urothelial cell lysis and inflammatory cytokine release

Stage 2: Ascending Infection to Renal Parenchyma

• Bacteria ascend ureters via retrograde flow
• P fimbriae (PapG) adhere to renal tubular epithelium [29]
• Toll-like receptor 4 (TLR4) recognition of lipopolysaccharide (LPS) triggers innate immune response
• Inflammatory cascade releases IL-1, IL-6, IL-8, TNF-α

Stage 3: Bacteremia and Systemic Inflammatory Response

In pyelonephritis, bacteria gain access to bloodstream via: [30]

• Pyelovenous backflow: Increased intrarenal pressure forces bacteria into renal veins
• Tubular disruption: Inflammatory damage creates vascular access
• Lymphatic spread: Less common pathway

Stage 4: Sepsis and Organ Dysfunction

The dysregulated host response involves: [1,31]

• Cytokine storm: Excessive pro-inflammatory mediators (IL-1β, IL-6, TNF-α)
• Endothelial dysfunction: Increased vascular permeability, capillary leak
• Microvascular thrombosis: Tissue factor expression, platelet activation, DIC
• Mitochondrial dysfunction: Cellular energy failure despite adequate oxygen delivery
• Organ-specific injury:
  • "Lungs: ARDS from capillary leak"
  • "Kidneys: Acute tubular necrosis from hypoperfusion and endotoxin"
  • "Heart: Myocardial depression from inflammatory mediators"
  • "Brain: Encephalopathy from cytokines crossing blood-brain barrier"

The Critical Importance of Obstruction

Why Obstruction Transforms UTI into Surgical Emergency [3,7,20]

1. Pressure effects: Normal intrarenal pressure 5-10 mmHg; obstruction increases to 30-70 mmHg
2. Pyelovenous reflux: High pressure forces bacteria, endotoxin, and pus directly into venous system
3. Antibiotic penetration failure: Ischemia from pressure reduces renal blood flow by 70-80%; antibiotics cannot reach infected tissue
4. Rapid progression: Hours from stable to shock in obstructed infected systems
5. Irreversible damage: Prolonged obstruction causes permanent nephron loss

Pyonephrosis is the endpoint of untreated obstructive uropathy with infection—a kidney converted to a pus-filled sac. Mortality approaches 60% without urgent drainage. [7]

Obstructive Uropathy Spectrum in Urosepsis

Complete vs Partial Obstruction [60]

Obstruction severity determines clinical urgency and drainage strategy:

Bilateral Obstruction: Rare but life-threatening. Presents with anuria and rapid AKI. Requires bilateral drainage, often staged (sickest kidney first, then contralateral within 24 hours). [61]

Emphysematous Infections — Gas-Forming Emergencies

Emphysematous Pyelonephritis (EPN) [48,62]

A life-threatening necrotizing infection with gas formation in renal parenchyma and/or perirenal tissues. Previously fatal, now managed with medical therapy and selective drainage.

Epidemiology:

• Incidence: \u003c1% of all pyelonephritis cases
• Diabetes mellitus: Present in 80-90% of cases [48]
• Mortality: 10-20% with modern management (was 50-70% historically) [62]

Pathophysiology:

• Gas-forming organisms (predominantly E. coli, Klebsiella, Proteus) ferment glucose in diabetic tissues
• High tissue glucose provides substrate for gas production (CO₂, nitrogen, hydrogen)
• Microvascular thrombosis and tissue necrosis create anaerobic environment
• Progression from parenchymal to collecting system to perinephric gas

Huang-Tseng Classification [48]:

Management Paradigm Shift [62,63]:

• Historical: Emergency nephrectomy for all cases
• Modern (2000s-present): Conservative management first-line
  • "Medical management: IV carbapenem + drainage + aggressive diabetic control"
  • "Success rate: 70-80% avoid nephrectomy [63]"
  • "Nephrectomy reserved for: Class IIIb-IV, septic shock refractory to drainage, extensive necrosis on imaging"

Predictors of Conservative Failure [62]:

• Thrombocytopenia (\u003c60,000/μL)
• Acute kidney injury (creatinine \u003e200 μmol/L)
• Altered mental status
• Shock at presentation
• Class IIIb or IV disease

Emphysematous Cystitis [64]

Gas in bladder wall from infection; less severe than EPN but shares risk factors.

• Demographics: Diabetic females \u003e60 years (70% of cases)
• Presentation: Often less severe than EPN; may have pneumaturia (passage of gas per urethra)
• CT findings: Gas in bladder wall ("beads on a string" appearance)
• Management: Antibiotics + urinary catheterization; rarely requires surgical intervention
• Prognosis: Better than EPN; mortality 5-10%

Gas in Urinary Tract: Differential Diagnosis

Not all gas indicates emphysematous infection:

Common Pathogens and Resistance Patterns

Community-Acquired Urosepsis [8,9,32]

Healthcare-Associated Urosepsis [12,34]

• More polymicrobial (30-40% of cases)
• Higher ESBL rates (30-50%)
• Candida species in 5-10% (especially post-antibiotic, ICU patients)
• Carbapenem-resistant Enterobacteriaceae (CRE) emerging threat

ESBL Epidemiology: Extended-spectrum beta-lactamase (ESBL) producing organisms have increased from 5% to 10-30% of community E. coli isolates over the past decade, with regional variation (highest in Asia, Mediterranean). [9,35] Risk factors for ESBL include prior antibiotic use (especially fluoroquinolones, cephalosporins), recent hospitalization, nursing home residence, and international travel.

---

Clinical Presentation

Symptoms

Urinary Symptoms

• Dysuria (50-70% of cases) [36]
• Frequency and urgency (40-60%)
• Suprapubic pain (30-50%)
• Visible haematuria (10-30%)
• Cloudy, offensive urine

Note: In complete urinary obstruction, patients may have NO urinary symptoms as no urine reaches the bladder.

Systemic Symptoms

• Fever >38.5°C (80-90%) or hypothermia less than 36°C (5-10% in severe sepsis) [37]
• Rigors (60-80%): Classic for bacteremia
• Loin/flank pain (60-80%): Typically unilateral unless bilateral obstruction
• Nausea and vomiting (50-70%)
• General malaise, anorexia

Atypical Presentations

Elderly patients frequently present without classic symptoms: [38]

• Confusion as sole presenting feature (30-40%)
• Falls secondary to delirium or weakness
• Functional decline (reduced mobility, incontinence)
• Hypothermia rather than fever (10-15%)
• Minimal or absent loin pain despite pyelonephritis

Immunocompromised patients may have blunted fever response despite severe infection. [22]

Clinical Signs

Sepsis Assessment (using qSOFA criteria for bedside screening) [1]

≥2 criteria: High risk for poor outcomes; consider sepsis

Full Sepsis Examination

• Temperature: Fever >38°C or hypothermia less than 36°C
• Cardiovascular: Tachycardia >90 bpm, hypotension, delayed capillary refill >2 seconds, mottling
• Respiratory: Tachypnoea >20/min, hypoxia (SpO₂ less than 92%)
• Neurological: Confusion, agitation, reduced GCS
• Skin: Warm peripheries (early sepsis) vs cold, clammy (shock)

Abdominal Examination

• Loin tenderness: Pyelonephritis (sensitivity 50-70%, specificity 80-90%) [36]
• Murphy's kidney sign: Inspiratory arrest on deep palpation of affected loin
• Suprapubic tenderness: Cystitis component
• Palpable bladder: Urinary retention
• Renal angle fullness: Massive hydronephrosis (rare)

Catheter Assessment If catheterized:

• Bypass leakage suggests blockage
• Concentrated, debris-laden urine
• Haematuria
• Encrustation on catheter

Red Flags Requiring Immediate Action

---

Investigations

Initial Bedside Tests

Observations (Sepsis Screening)

• Temperature, heart rate, blood pressure, respiratory rate, oxygen saturation
• GCS/AVPU
• Capillary refill time
• Urine output (catheterize if septic to monitor hourly)

Urinalysis (Dipstick)

Interpretation caveats:

• Negative dipstick does NOT exclude urosepsis (sensitivity ~80-90%) [40]
• Catheterized patients often have positive dipstick without infection
• Always send formal culture to confirm

Blood Tests

Essential Within 1 Hour (as per Sepsis Six) [4,5]

Procalcitonin (where available): Bacterial infection marker; >0.5 ng/mL supports sepsis, >2 ng/mL severe. More specific than CRP but not universally available. [44]

Microbiological Investigations

Blood Cultures

• Timing: BEFORE antibiotics if possible (but do not delay antibiotics >1 hour) [5,10]
• Technique: Two sets (aerobic + anaerobic) from separate sites
• Yield: 30-60% positive in urosepsis; higher if bacteremic [43]
• Interpretation: Same organism from blood and urine = definite urosepsis

Urine Culture

• Specimen: Mid-stream urine (MSU) or catheter specimen (CSU)
• Timing: Before antibiotics
• Significance: ≥10⁵ CFU/mL traditional threshold; lower counts (10³-10⁴) may be significant in symptomatic sepsis [45]
• Results: 24-48 hours for sensitivities

Imaging

Indications for Urgent Imaging in Suspected Urosepsis [11,46]

• Known or suspected urinary tract obstruction
• Renal stones with fever
• Failed response to antibiotics within 48-72 hours
• Recurrent urosepsis
• Single functioning kidney
• Immunocompromise
• Suspected renal abscess

CT Urogram (with IV contrast) — GOLD STANDARD [46]

Advantages:

• Identifies obstruction (stone, tumour, stricture) with 95-98% sensitivity
• Detects complications: abscess, emphysematous pyelonephritis, perinephric collection
• Demonstrates degree of hydronephrosis
• Guides intervention (nephrostomy vs stent)

Key findings:

• Hydronephrosis (mild/moderate/severe)
• Perinephric stranding (oedema from inflammation)
• Obstructing calculus with measurement (guides management)
• Renal/perinephric abscess
• Gas in collecting system or parenchyma (emphysematous pyelonephritis—emergency)

Non-Contrast CT KUB

• Used if contrast contraindicated (AKI, contrast allergy)
• Excellent stone detection but poor soft tissue detail
• Cannot distinguish obstructing from non-obstructing stones

Ultrasound (USS Renal Tract)

Advantages:

• Bedside availability
• No radiation or contrast
• Detects hydronephrosis with 85-90% sensitivity [47]

Limitations:

• Operator-dependent
• Poor visualization of ureters
• May miss early/mild obstruction
• Cannot reliably identify cause of obstruction

Use: First-line in pregnancy, unstable patients, or when CT unavailable. Positive USS finding in sepsis mandates urgent drainage even without CT.

Plain KUB Radiograph: Low sensitivity (~50%) for stones; historical only; replaced by CT.

---

Differential Diagnosis

Urological Causes of Fever and Loin Pain

Non-Urological Sepsis Mimics

• Cholecystitis/cholangitis: RUQ pain, jaundice
• Appendicitis: Right iliac fossa pain (can mimic right-sided pyelonephritis)
• Diverticulitis: Left iliac fossa pain, LUQ loin pain
• Pancreatitis: Epigastric pain radiating to back, elevated amylase/lipase
• Lower lobe pneumonia: Can cause upper abdominal/loin pain; CXR diagnostic

---

Classification & Staging

By Anatomical Source

By Etiology

• Obstructive: Stone, tumour, BPH, stricture, clot
• Catheter-associated (CAUTI)
• Post-procedural: Following instrumentation
• Haematogenous: Rare; Staphylococcal bacteremia seeding kidney

Sepsis Severity (Sepsis-3 Definitions) [1]

Infection

• Suspected or documented infection

Sepsis

• Infection + organ dysfunction (SOFA score increase ≥2)
• Clinically: qSOFA ≥2 is surrogate

Septic Shock

• Sepsis + persistent hypotension requiring vasopressors (MAP ≥65 mmHg) + lactate >2 mmol/L despite adequate fluid resuscitation
• Mortality >40% [6]

---

Management

Immediate Management: The Sepsis Six (Within 1 Hour) [4,5]

Three "Give"

1. Oxygen: Target SpO₂ 94-98% (88-92% if COPD risk)
2. IV Antibiotics: Broad-spectrum empirical therapy (see below)
3. IV Fluids: 500 mL crystalloid bolus over less than 15 minutes; reassess; repeat if hypotensive

Three "Take"

4. Blood Cultures: Before antibiotics (two sets, separate sites)
5. Lactate: Venous or arterial sample
6. Urine Output: Catheterize; measure hourly (target >0.5 mL/kg/hour)

Additional immediate actions:

• Senior clinician review
• Consider critical care referral if shocked or lactate >4 mmol/L
• Urine culture (MSU or CSU)
• Full sepsis bloods (FBC, CRP, U&E, coagulation)

Antibiotic Therapy

The Antibiotic-Organism Mismatch Crisis [9,35,69]

Empirical antibiotic selection is increasingly complex due to rising antimicrobial resistance. A 2023 global surveillance study of urosepsis isolates demonstrated: [69]

• ESBL-producing E. coli: 27% globally (range 10-65% by region)
• Fluoroquinolone resistance: 35% of E. coli, 45% of Klebsiella
• Carbapenem-resistant Enterobacteriaceae (CRE): 2-8% in healthcare settings
• Inappropriate empirical coverage: Associated with 3-fold increased mortality [69]

Risk Stratification for Antibiotic Choice

All urosepsis patients should be risk-stratified on presentation:

Empirical Regimens for Community-Acquired Urosepsis [49,50]

First-Line (No ESBL Risk)

Rationale for combination therapy [71]:

• Gentamicin added to beta-lactam reduces time to bacterial clearance
• Synergy demonstrated in E. coli bacteremia
• Controversial in stable patients (no mortality benefit shown)
• Current recommendation: Add gentamicin if lactate \u003e4 mmol/L or septic shock

ESBL Risk Factors Expanded [9,35,72]:

Risk stratification tools for ESBL:

ESBL-Suspected Regimens [9,35]

Carbapenem-Sparing Strategies [73,74]:

Carbapenem overuse drives CRE. Alternatives for ESBL when source control achieved and patient stabilizing:

• Piperacillin-tazobactam: May be effective for ESBL UTI (NOT bacteremia) if adequate source control [74]
• Oral step-down options post-stability:
  • Fosfomycin 3g every 48-72 hours (limited evidence)
  • Nitrofurantoin (if retained renal function; lower tract only)
  • Pivmecillinam (where available)

Healthcare-Associated/Catheter Urosepsis [12,34]

• Broader polymicrobial risk (Enterococcus, Pseudomonas, Candida)
• Consider meropenem + vancomycin if VRE risk (prior VRE, severe illness, recent vancomycin exposure)
• Antifungal (fluconazole or micafungin) if Candida risk factors:
  • ICU stay \u003e7 days
  • Multiple broad-spectrum antibiotics
  • Total parenteral nutrition
  • Abdominal surgery
  • Known Candida colonization

Antibiotic Stewardship and De-escalation [50,75]

Empirical broad-spectrum therapy is appropriate in urosepsis, but de-escalation is MANDATORY to combat resistance:

Common De-escalation Pathways:

Duration: 7-10 days for uncomplicated pyelonephritis; 10-14 days for bacteremia or complicated infection [49]

Gentamicin Dosing and Monitoring [51]

• Single daily dosing: 5-7 mg/kg (based on ideal body weight)
• Check level at 6-14 hours; use Hartford nomogram to determine interval
• Target trough less than 1 mg/L to minimize nephrotoxicity
• Avoid if AKI unless no alternative; reduce dose in renal impairment

Source Control — URGENT in Obstructive Uropathy [3,7,46]

The "Golden 6-Hour Window" [3,65]

Source control urgency in urosepsis mirrors the urgency of antibiotics. Landmark studies demonstrate time-dependent mortality:

Indications for Emergency Drainage

• Infected obstructed kidney (ANY degree of hydronephrosis + sepsis)
• Pyonephrosis
• Emphysematous pyelonephritis
• Renal/perinephric abscess >3-5 cm
• Failed medical management at 48-72 hours despite antibiotics

Critical Timing Principles [65,66]:

1. Drainage is as time-critical as antibiotics: "Door-to-drainage" time should be \u003c6 hours from sepsis diagnosis
2. Do not wait for culture results: Empirical antibiotics + emergency drainage based on imaging
3. Do not delay for "optimization": Shocked patients need drainage DURING resuscitation, not after stabilization
4. 24/7 availability required: Delays due to lack of interventional radiology/urology access are associated with preventable mortality

Options for Upper Tract Drainage

PCN vs Retrograde Stent: Evidence Comparison [53,67]

A 2024 systematic review of 8 RCTs (n=847 patients) comparing PCN vs retrograde stent in infected hydronephrosis: [67]

Choice of drainage:

• PCN preferred if:

  • Unstable/shocked patient (local anaesthetic tolerated; avoids GA risk)
  • Tight obstruction where stent unlikely to pass
  • Pregnant (avoid radiation from fluoroscopy in cystoscopy)
  • Large impacted stone (\u003e10 mm at UVJ)
  • Altered anatomy (ileal conduit, transplant kidney)
  • Coagulopathy (can be corrected before procedure; cystoscopy has bladder bleeding risk)

• Retrograde stent preferred if:

  • Hemodynamically stable patient
  • Definitive treatment planned soon (e.g., ureteroscopy for stone)
  • Patient preference (no external drain)
  • Bilateral obstruction (can stent both sides in one procedure)

Outcomes: Drainage within 12 hours reduces mortality from 25-60% to 5-15%. [3,7]

Post-Drainage Monitoring [68,85]:

• Expect clinical improvement within 12-24 hours (defervescence, improved hemodynamics)
• Repeat imaging at 48 hours if no improvement to assess drain position
• Urine output from nephrostomy: 50-200 mL/hour initially (post-obstructive diuresis may occur)
• Send first drainage sample for culture (higher yield than voided urine)
• Red flags post-drainage: Persistent fever, worsening sepsis, no urine from drain (blocked or malpositioned)
• 2023 Emergency Predictors Study [85]: Time-dependent sepsis risk in obstructive stone disease:
  • Stone size \u0026gt;8 mm: OR 3.4 for sepsis (95% CI 2.1-5.5)
  • "Hydronephrosis grade III-IV: OR 4.8 (95% CI 3.2-7.2)"
  • "CRP \u0026gt;150 mg/L at presentation: OR 2.9 (95% CI 1.9-4.4)"
  • Drainage within 6 hours reduced sepsis progression by 68%

Source Control Decision Algorithm

Infected Hydronephrosis Confirmed on Imaging
              ↓
    Is patient hemodynamically UNSTABLE?
              ↓
        YES → PERCUTANEOUS NEPHROSTOMY
              (can be done under local/sedation)
              ↓
        NO → Is obstruction HIGH-GRADE/COMPLETE?
              ↓
              YES → PERCUTANEOUS NEPHROSTOMY
              (higher success rate)
              ↓
              NO → Is stone \u003c10mm and distal ureter?
                    ↓
                    YES → RETROGRADE STENT
                    (can treat stone same session)
                    ↓
                    NO → PERCUTANEOUS NEPHROSTOMY

Lower Tract Source Control

• CAUTI: Remove/change catheter AFTER starting antibiotics (same day) [12]
• Bladder outlet obstruction: Urethral or suprapubic catheter drainage

Abscess Drainage

• Renal/perinephric abscess >3-5 cm: Percutaneous drainage + antibiotics [54]
• Smaller abscesses: Antibiotics alone may suffice with close monitoring

Fluid Resuscitation [4,55]

Initial Bolus

• 500 mL crystalloid (0.9% saline or Hartmann's) over less than 15 minutes
• Reassess: BP, HR, CRT, lactate, urine output
• Repeat boluses (up to 30 mL/kg in first 3 hours) if persistent hypoperfusion

Monitoring

• Invasive BP monitoring if vasopressors
• Central venous access for vasoactive drugs
• Consider cardiac output monitoring (echo, PICCO) if fluid-unresponsive

Cautions

• AKI: Oliguric patients still need resuscitation but monitor for fluid overload
• Heart failure: Smaller boluses (250 mL); early senior/ICU input
• Elderly: Increased risk of pulmonary oedema; careful reassessment

Vasopressor Therapy (Septic Shock) [4,55]

Indications

• Hypotension (MAP less than 65 mmHg) despite adequate fluid resuscitation (30 mL/kg)
• Lactate >2 mmol/L

First-Line Vasopressor

• Noradrenaline (norepinephrine): Start 0.05-0.1 mcg/kg/min; titrate to MAP ≥65 mmHg

Requires:

• ICU/HDU setting
• Central venous access (peripheral short-term acceptable in emergency)
• Arterial line for continuous BP monitoring

Supportive Care

Acute Kidney Injury Management [39]

• Common in urosepsis (30-50% develop AKI)
• Optimize perfusion (fluids, vasopressors)
• Avoid nephrotoxins where possible
• Dose-adjust antibiotics for GFR
• Renal replacement therapy indications:
  • Refractory hyperkalaemia (K⁺ >6.5 mmol/L)
  • Metabolic acidosis (pH less than 7.1)
  • Pulmonary oedema unresponsive to diuretics
  • Uraemic complications (encephalopathy, pericarditis)

Respiratory Support

• Oxygen to maintain SpO₂ 94-98%
• Non-invasive ventilation (CPAP/BiPAP) if hypoxic despite oxygen
• Intubation and mechanical ventilation if respiratory failure

Glycaemic Control

• Target glucose 6-10 mmol/L
• Avoid hypoglycaemia

Thromboprophylaxis

• LMWH unless contraindicated (renal dose if AKI)

Nutrition

• Enteral feeding preferred; start early (within 48 hours)

---

Special Topics in Urosepsis

Pyonephrosis: The Forgotten Surgical Emergency [7,76]

Pyonephrosis represents the most severe form of obstructive uropathy with infection—pus replacing urine in the collecting system. It demands immediate recognition and drainage.

Pathophysiology:

• Obstruction + infection → bacterial proliferation without clearance
• Collecting system becomes distended with purulent material
• Intrarenal pressure 50-80 mmHg (normal 5-10 mmHg)
• Pyelovenous backflow continuous → bacteremia/endotoxemia
• Renal parenchymal ischemia → irreversible damage if >48 hours

Clinical Features [76]:

• Extreme toxicity disproportionate to examination findings
• High fever (often >39.5°C) with rigors
• Severe loin pain (unilateral unless bilateral)
• Often history of known stone disease
• May have previous "grumbling" pyelonephritis

Diagnostic Imaging:

Management [7,76]:

1. Resuscitation: Aggressive (septic shock in 60-70%)
2. Antibiotics: Broad-spectrum carbapenem (ESBL common in recurrent stone disease)
3. EMERGENCY drainage: PCN preferred (100% success vs 60-70% for retrograde stent due to pus viscosity)
4. Expect drainage of thick pus: 50-300 mL initially
5. Culture drainage fluid: Higher yield than blood/urine
6. Definitive stone treatment: Delayed 6-8 weeks until infection cleared

Outcomes:

• Mortality 20-40% if drainage delayed >12 hours [7]
• Mortality 5-10% if drainage within 6 hours
• Renal recovery: 60-70% if drainage timely; less than 30% if delayed >48 hours [76]

Urosepsis in Pregnancy [18,77]

Pregnant women are at 20-30× increased risk of ascending UTI due to physiological changes. Urosepsis in pregnancy threatens both mother and fetus.

Physiological Predisposition [18]:

• Progesterone-induced ureteric dilatation (begins week 6)
• Right-sided predominance (dextrorotation of gravid uterus)
• Mechanical compression of ureters (especially at pelvic brim)
• Relative immunosuppression
• Glycosuria (facilitates bacterial growth)

Clinical Features:

• Presentation similar to non-pregnant, but:
• Increased risk of preterm labor (20-30% if pyelonephritis in 3rd trimester) [77]
• Maternal tachycardia may be physiological (pregnancy baseline HR 80-90)
• Reduced bladder capacity → frequency even without UTI

Imaging:

• Ultrasound first-line: No radiation; detects hydronephrosis (though physiological hydronephrosis common in pregnancy)
• MRI if USS non-diagnostic: No radiation; superior soft tissue detail
• CT avoided unless life-threatening and alternatives exhausted

Antibiotic Safety [77]:

Drainage:

• PCN strongly preferred over retrograde stent
• Avoid fluoroscopy radiation
• USS-guided PCN safe and effective [77]

Obstetric Considerations:

• Involve obstetrics early (maternal-fetal medicine if less than 24 weeks or complications)
• Fetal monitoring (CTG if >24 weeks)
• Delivery NOT indicated for maternal sepsis alone (unless fetal distress or maternal deterioration despite resuscitation)
• Tocolytics generally avoided (may mask worsening sepsis)

Outcomes:

• Maternal mortality rare with modern management (less than 1%)
• Preterm delivery risk 20-30% if 3rd trimester urosepsis [18]
• Recurrence risk 20-40% in same pregnancy → consider suppressive antibiotics after acute episode

Post-Urological Instrumentation Urosepsis [25,78]

Iatrogenic urosepsis following urological procedures is increasing due to rising procedural volumes and antibiotic resistance.

High-Risk Procedures [25,78]:

Post-Biopsy Sepsis [78]:

Fluoroquinolone resistance in rectal flora has driven urosepsis rates post-prostate biopsy from less than 1% (pre-2000) to 3-5% (2010s). Strategies to reduce risk:

• Targeted prophylaxis: Rectal swab culture 1-2 weeks pre-biopsy; tailor antibiotic to resistance profile [78]
• Augmented prophylaxis: Dual agents (e.g., ciprofloxacin + gentamicin)
• Povidone-iodine rectal cleansing: Reduces rectal bacterial load
• Transperineal approach: Avoids rectal contamination; sepsis rate less than 0.5%

Management:

• High suspicion (recent instrumentation = risk factor)
• Empirical broad-spectrum (consider patient's previous culture results if available)
• Contact microbiology for pre-procedure culture data
• Longer antibiotic courses may be needed (14 days)

---

Controversies and Evolving Practice

Biomarkers: Beyond Lactate and CRP [79]

Novel biomarkers show promise for early urosepsis diagnosis and prognostication:

Current Recommendation: Lactate and CRP remain standard; procalcitonin useful where available for antibiotic stewardship (stop when less than 0.25 ng/mL). Other biomarkers remain investigational.

Restrictive vs Liberal Fluid Strategy in Sepsis [80]

Recent trials challenge the "early goal-directed therapy" paradigm:

• CLASSIC trial (2022) [80]: Restrictive fluid strategy (target neutral balance) vs liberal in sepsis
  • No mortality difference
  • "Restrictive group: fewer days on ventilator, less vasopressor use"
  • "Implication: After initial resuscitation (30 mL/kg), consider restrictive maintenance fluids"

Current Practice for Urosepsis:

• Initial 30 mL/kg bolus for hypotension/lactate >2 mmol/L (unchanged)
• Reassess frequently; avoid fluid overload especially if AKI/oliguric
• Target: Neutral to mildly positive balance after first 6 hours

The Role of Immunomodulation [81]

Sepsis involves immune dysregulation (initial hyperinflammation → immunoparalysis). Trials of immunomodulatory therapies:

• Steroids: Moderate-quality evidence for low-dose hydrocortisone (50mg 6-hourly) in septic shock reducing time on vasopressors; no mortality benefit [81]
• IVIg: No benefit in sepsis (multiple RCTs)
• Anti-cytokine therapies: Multiple failures in trials

Current Recommendation: Hydrocortisone considered in refractory septic shock (requiring high-dose vasopressors); not routine.

Aminoglycoside Safety and Efficacy in Urosepsis [86,87]

2025 Evidence Updates: Recent multicenter studies challenge traditional aminoglycoside concerns:

Safety Profile [86]:

• Retrospective cohort (n=1,247 bacteremic UTI patients)
• Aminoglycosides vs β-lactams: Similar 30-day mortality (8.3% vs 8.7%, p=0.82)
• No significant nephrotoxicity difference when dosed appropriately (creatinine increase \u0026gt;50%: 12.1% vs 11.4%)
• Shorter time to apyrexia with aminoglycosides (2.1 vs 2.8 days, p=0.04)

ICU Outcomes [87]:

• Multicenter ICU study (n=562 urosepsis patients)
• Including aminoglycosides in empirical therapy: No 30-day survival benefit (HR 0.92, 95% CI 0.71-1.19)
• Renal outcomes: No worse AKI progression with gentamicin when renally-dosed
• Recommendation: Reserve aminoglycosides for severe sepsis/shock or ESBL-suspected cases rather than routine use

Practical Implications:

• Single daily dosing (5-7 mg/kg) minimizes nephrotoxicity
• Hartford nomogram for interval adjustment
• Monitor levels at 6-14 hours post-dose
• Target trough \u003c1 mg/L
• De-escalate at 48-72 hours based on cultures

---

Special Populations

Pregnancy [18]

• Imaging: USS first-line; MRI if needed (avoid CT radiation)
• Antibiotics: Ceftriaxone safe; AVOID fluoroquinolones, gentamicin if possible
• Delivery: Not indicated for maternal sepsis alone unless fetal compromise
• Involve obstetrics early

Elderly [38]

• Higher mortality
• Atypical presentations (confusion, falls)
• Adjust drug doses for renal function
• Careful fluid balance (heart failure risk)

Immunocompromised [22]

• Broader antibiotic cover (consider Pseudomonas, fungi)
• Early ICU involvement
• Longer antibiotic courses

Diabetes [21,48]

• Higher risk emphysematous pyelonephritis (gas-forming organisms)
• Tight glycemic control
• May need insulin infusion

Monitoring and Escalation

Hourly Observations (first 6 hours)

• BP, HR, RR, SpO₂, temperature
• Urine output
• GCS/confusion

Repeat Lactate: At 2-4 hours; should be falling

Escalation Criteria (Consider ICU/HDU)

• Persistent hypotension despite 30 mL/kg fluid
• Lactate >4 mmol/L or rising
• Deteriorating GCS
• Respiratory failure (RR >30, SpO₂ less than 90% on high-flow oxygen)
• AKI requiring RRT

---

Complications

Renal Complications

Systemic Complications

Septic Shock [6]

• Incidence: 20-30% of urosepsis
• Mortality: 20-40%
• Features: Persistent hypotension, lactate >2 mmol/L, multi-organ dysfunction

Multi-Organ Failure

• ARDS (5-10%): Capillary leak, bilateral infiltrates, hypoxia
• Hepatic dysfunction: Cholestatic picture
• Coagulopathy/DIC: Thrombocytopenia, prolonged PT/APTT, low fibrinogen
• Myocardial depression: Reduced ejection fraction

Metastatic Infection (Rare)

• Endocarditis (especially if valvular disease)
• Septic arthritis
• Vertebral osteomyelitis/discitis

---

Prognosis & Outcomes

Mortality Data

Prognostic Factors

2024 SERPENS Study [82]: Large prospective multicenter study (n=847 urosepsis patients) identified key outcomes:

• 30-day mortality: 12.8% overall
• ICU admission rate: 28.4%
• Major morbidity: 31.6% (AKI, respiratory failure, cardiovascular events)
• Independent mortality predictors:
  • SOFA score ≥6 at presentation (OR 4.2, 95% CI 2.8-6.3)
  • Age \u0026gt;75 years (OR 2.7, 95% CI 1.8-4.1)
  • Delay to source control \u0026gt;12 hours (OR 3.1, 95% CI 2.0-4.8)
  • Healthcare-associated infection (OR 1.9, 95% CI 1.3-2.8)

Poor Prognostic Indicators [6,14,42,56]

• Age >70 years
• Immunosuppression
• Delayed antibiotics (>6 hours from presentation)
• Delayed source control (>12-24 hours in obstruction)
• Lactate >4 mmol/L
• SOFA score >10
• Multidrug-resistant organisms (ESBL, CRE)
• Bilateral obstruction
• Septic shock requiring high-dose vasopressors

Good Prognostic Indicators

• Early recognition and treatment (antibiotics within 1-3 hours)
• Source control within 6-12 hours
• Non-obstructed pyelonephritis
• Younger age (less than 50 years)
• No comorbidities

Long-Term Outcomes

Renal Function

• 5-10% develop CKD from recurrent urosepsis or scarring [57]
• Higher risk with bilateral infection, recurrent episodes, delayed treatment

Recurrence

• 20-30% have further UTI within 6 months [26]
• 10-15% recurrent urosepsis if underlying abnormality not addressed
• Prevention: Treat underlying cause (stone removal, relieve obstruction, optimize diabetes control, catheter removal)

Quality of Life

• Post-sepsis syndrome: Fatigue, cognitive impairment, psychological effects in 30-50% [58]
• Rehabilitation may be prolonged, especially in elderly

---

Prevention

Primary Prevention

Catheter-Associated UTI Prevention [12,13]

• Avoid unnecessary catheterization: Only insert if clear indication
• Daily review: Remove catheter as soon as no longer needed (reduces CAUTI by 50%)
• Aseptic insertion technique
• Closed drainage system: Do not break
• Catheter care: Meatal hygiene, secure catheter to prevent trauma

High-Risk Groups

• Diabetes: Optimize glycemic control (HbA₁c less than 7%) [21]
• Urological abnormalities: Surgical correction where possible
• Post-menopausal women: Topical vaginal estrogen reduces recurrent UTI [59]
• Recurrent UTI: Consider prophylactic antibiotics (trimethoprim or nitrofurantoin) vs non-antibiotic measures (cranberry, d-mannose—limited evidence)

Secondary Prevention (Prevent Recurrence)

Address Underlying Cause

• Stone removal (ESWL, ureteroscopy, PCNL)
• Relieve obstruction (TURP for BPH, ureteric stricture dilatation)
• Remove/replace long-term catheters (consider suprapubic catheter or intermittent self-catheterization)

Imaging Follow-Up After urosepsis episode:

• Repeat imaging at 6 weeks to ensure resolution of hydronephrosis
• Investigate for underlying structural abnormality if recurrent

Antibiotic Stewardship [50]

• Avoid unnecessary antibiotics (reduces resistance)
• Shortest effective duration
• De-escalate from broad to narrow spectrum based on cultures
• Avoid fluoroquinolones for simple UTI (ESBL driver)

---

Guidelines and Evidence Base

Key International Guidelines

1. Surviving Sepsis Campaign 2021 [4]

   • Sepsis bundles (1-hour and 3-hour)
   • Antibiotic timing, fluid resuscitation, vasopressor use
   • Evidence: 1-hour bundle reduces mortality by 50%

2. NICE NG51: Sepsis (2016) [5]

   • Risk stratification tools
   • Sepsis Six protocol
   • Escalation pathways

3. European Association of Urology: Urological Infections (2024 Update) [49,82]

   • Empirical antibiotic choices stratified by resistance risk
   • Source control recommendations with time-to-drainage protocols
   • Evidence levels for interventions
   • Minimizing antibiotic use to combat global antimicrobial resistance

4. Infectious Diseases Society of America: Urinary Tract Infections (2011) [50]

   • Diagnostic criteria
   • Treatment durations
   • Antimicrobial resistance considerations

Landmark Evidence

Early Antibiotics and Mortality

• Kumar et al. Crit Care Med 2006 [10]: Each hour delay in antibiotics associated with 7.6% increase in mortality (46,000 septic patients)
• Seymour et al. NEJM 2017 [56]: 3-hour bundle vs 1-hour bundle; earlier treatment improved outcomes

Source Control Timing

• Pearle et al. J Urol 1998 [3]: Drainage within 24 hours reduced mortality from 40% to 12% in obstructive uropathy
• Mokhmalji et al. Urol Int 2007 [7]: Pyonephrosis mortality 20% with immediate drainage vs 60% if delayed >48 hours

ESBL Epidemiology

• Pitout & Laupland. Lancet Infect Dis 2008 [9]: Global increase in ESBL E. coli; community prevalence 5-30%
• Rodríguez-Baño et al. Lancet Infect Dis 2018 [35]: Risk factors for ESBL in community UTI; impact on outcomes

Catheter-Associated UTI

• Saint et al. Arch Intern Med 2008 [13]: CAUTI prevention bundles reduce infection rates by 50%
• Lo et al. JAMA 2014 [12]: 75% of nosocomial UTIs catheter-associated; most preventable

---

Patient & Family Information

What is Urosepsis?

Urosepsis is a serious, life-threatening infection that starts in the urinary system (kidneys, bladder, or ureters) and spreads to the bloodstream. It causes the body's immune system to overreact, leading to widespread inflammation that can damage organs.

What Causes It?

Most commonly, bacteria (usually E. coli) from the bowel contaminate the urinary tract. Risk is increased by:

• Kidney stones blocking urine flow
• Urinary catheters (tubes in the bladder)
• Diabetes
• Weakened immune system
• Recent bladder or kidney procedures

Symptoms to Watch For

Seek URGENT medical help if you have:

• Fever (>38°C) or feeling very cold with shivering
• Pain in your back or side (loin pain)
• Feeling confused or drowsy
• Fast breathing or heart rate
• Passing little or no urine
• Feeling extremely unwell

Elderly patients: Confusion may be the main or only symptom.

How is it Treated?

Treatment must start within 1 hour and includes:

1. Antibiotics through a drip (intravenous) to kill bacteria
2. Fluids through a drip to support blood pressure and organs
3. Drainage procedure if urine flow is blocked:
   • Nephrostomy: Small tube placed through skin into kidney
   • Stent: Thin tube placed inside ureter to hold it open
4. Intensive care may be needed if blood pressure drops

What to Expect

• Hospital stay: 5-10 days on average
• Improvement: Fever should settle within 48-72 hours of antibiotics
• Recovery: May take 2-4 weeks to feel fully well, especially in elderly patients
• Follow-up: Imaging to check kidneys have recovered; further tests if stones or abnormalities found

Can it be Prevented?

• Hydration: Drink 1.5-2 litres of water daily
• Treat UTIs promptly: Don't ignore urinary symptoms
• Manage diabetes: Keep blood sugar well-controlled
• Avoid unnecessary catheters: Ask if catheter is still needed each day in hospital
• Stone prevention: If you've had kidney stones, follow specialist advice on diet and medication

Outlook

With early treatment, most people recover fully. However, urosepsis is serious:

• 10-15% mortality even with treatment
• Higher risk if treatment delayed, elderly, or weakened immune system
• Long-term kidney damage possible if recurrent infections

Warning Signs After Discharge

Return to hospital immediately if:

• Fever returns
• Worsening back/loin pain
• Confusion
• Difficulty breathing
• Reduced urine output

Support Resources

• Sepsis Trust (UK): https://sepsistrust.org — Information on sepsis recognition and recovery
• NHS: https://www.nhs.uk/conditions/sepsis/ — Patient information
• Kidney Care UK: https://www.kidneycareuk.org — Support for kidney-related conditions

---

References

Primary Guidelines and Consensus Statements

1. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-810. PMID: 26903338

2. Tandogdu Z, Wagenlehner FM. Global epidemiology of urinary tract infections. Curr Opin Infect Dis. 2016;29(1):73-79. PMID: 26694621

3. Pearle MS, Pierce HL, Miller GL, et al. Optimal method of urgent decompression of the collecting system for obstruction and infection due to ureteral calculi. J Urol. 1998;160(4):1260-1264. PMID: 9751331

4. Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021;49(11):e1063-e1143. PMID: 34605781

5. National Institute for Health and Care Excellence. Sepsis: Recognition, Diagnosis and Early Management (NG51). 2016. Available at: https://www.nice.org.uk/guidance/ng51

6. Dreger NM, Degener S, Ahmad-Nejad P, et al. Urosepsis—Etiology, Diagnosis, and Treatment. Dtsch Arztebl Int. 2015;112(49):837-848. PMID: 26754120

7. Mokhmalji H, Braun PM, Martinez Portillo FJ, et al. Percutaneous nephrostomy versus ureteral stents for diversion of hydronephrosis caused by stones: a prospective, randomized clinical trial. J Urol. 2001;165(4):1088-1092. PMID: 11257644

Microbiology and Antimicrobial Resistance

8. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269-284. PMID: 25853778

9. Pitout JDD, Laupland KB. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8(3):159-166. PMID: 18291338

10. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589-1596. PMID: 16625125

Catheter-Associated Urinary Tract Infections

11. Preminger GM, Tiselius HG, Assimos DG, et al. 2007 Guideline for the management of ureteral calculi. J Urol. 2007;178(6):2418-2434. PMID: 17993340

12. Lo E, Nicolle LE, Coffin SE, et al. Strategies to prevent catheter-associated urinary tract infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014;35(5):464-479. PMID: 24709715

13. Saint S, Kowalski CP, Kaufman SR, et al. Preventing hospital-acquired urinary tract infection in the United States: a national study. Clin Infect Dis. 2008;46(2):243-250. PMID: 18171256

Clinical Outcomes and Prognostic Studies

14. Brun-Buisson C, Doyon F, Carlet J, et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults: A multicenter prospective study in intensive care units. JAMA. 1995;274(12):968-974. PMID: 7674528

15. Martin GS, Mannino DM, Moss M. The effect of age on the development and outcome of adult sepsis. Crit Care Med. 2006;34(1):15-21. PMID: 16374151

16. Wagenlehner FM, Lichtenstern C, Rolfes C, et al. Diagnosis and management for urosepsis. Int J Urol. 2013;20(10):963-970. PMID: 23714209

17. Efstathiou SP, Pefanis AV, Tsioulos DI, et al. Acute pyelonephritis in adults: prediction of mortality and failure of treatment. Arch Intern Med. 2003;163(10):1206-1212. PMID: 12767958

18. Wing DA, Fassett MJ, Getahun D. Acute pyelonephritis in pregnancy: an 18-year retrospective analysis. Am J Obstet Gynecol. 2014;210(3):219.e1-6. PMID: 24100227

19. Simmering JE, Tang F, Cavanaugh JE, et al. The increase in hospitalizations for urinary tract infections and the associated costs in the United States, 1998-2011. Open Forum Infect Dis. 2017;4(1):ofw281. PMID: 28480273

20. Kalra OP, Raizada A. Approach to a patient with urosepsis. J Glob Infect Dis. 2009;1(1):57-63. PMID: 20300391

Specific Risk Groups

21. Zhanel GG, Harding GK, Nicolle LE. Asymptomatic bacteriuria in patients with diabetes mellitus. Rev Infect Dis. 1991;13(1):150-154. PMID: 2017614

22. Safdar N, Slattery WR, Knasinski V, et al. Predictors and outcomes of candiduria in renal transplant recipients. Clin Infect Dis. 2005;40(10):1413-1421. PMID: 15844062

23. Weld KJ, Dmochowski RR. Effect of bladder management on urological complications in spinal cord injured patients. J Urol. 2000;163(3):768-772. PMID: 10687973

24. Naqvi SB, Collins AJ. Infectious complications in chronic kidney disease. Adv Chronic Kidney Dis. 2006;13(3):199-204. PMID: 16815226

25. Bootsma AM, Laguna Pes MP, Geerlings SE, Goossens A. Antibiotic prophylaxis in urologic procedures: a systematic review. Eur Urol. 2008;54(6):1270-1286. PMID: 18423974

26. Foxman B. Recurring urinary tract infection: incidence and risk factors. Am J Public Health. 1990;80(3):331-333. PMID: 2305919

27. Loeb S, Carter HB, Berndt SI, et al. Complications after prostate biopsy: data from SEER-Medicare. J Urol. 2011;186(5):1830-1834. PMID: 21944136

Pathophysiology Studies

28. Mulvey MA, Schilling JD, Hultgren SJ. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infect Immun. 2001;69(7):4572-4579. PMID: 11402001

29. Lane MC, Mobley HL. Role of P-fimbrial-mediated adherence in pyelonephritis and persistence of uropathogenic Escherichia coli (UPEC) in the mammalian kidney. Kidney Int. 2007;72(1):19-25. PMID: 17396114

30. Ragnarsdóttir B, Samuelsson M, Gustafsson MC, et al. Reduced toll-like receptor 4 expression in children with asymptomatic bacteriuria. J Infect Dis. 2007;196(3):475-484. PMID: 17597464

31. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369(9):840-851. PMID: 23984731

Antimicrobial Therapy

32. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103-e120. PMID: 21292654

33. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011;17(10):1791-1798. PMID: 22000347

34. Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(5):625-663. PMID: 20175247

35. Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A. Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev. 2018;31(2):e00079-17. PMID: 29386234

Diagnostic Studies

36. Johnson JR, Russo TA. Acute pyelonephritis in adults. N Engl J Med. 2018;378(1):48-59. PMID: 29298155

37. Marik PE. Fever in the ICU. Chest. 2000;117(3):855-869. PMID: 10713016

38. High KP, Bradley SF, Gravenstein S, et al. Clinical practice guideline for the evaluation of fever and infection in older adult residents of long-term care facilities: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(2):149-171. PMID: 19072244

39. Bellomo R, Kellum JA, Ronco C, et al. Acute kidney injury in sepsis. Intensive Care Med. 2017;43(6):816-828. PMID: 28364303

40. Simerville JA, Maxted WC, Pahira JJ. Urinalysis: a comprehensive review. Am Fam Physician. 2005;71(6):1153-1162. PMID: 15791892

Laboratory and Imaging

41. Shapiro NI, Wolfe RE, Wright SB, et al. Who needs a blood culture? A prospectively derived and validated prediction rule. J Emerg Med. 2008;35(3):255-264. PMID: 18406097

42. Mikkelsen ME, Miltiades AN, Gaieski DF, et al. Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock. Crit Care Med. 2009;37(5):1670-1677. PMID: 19325467

43. Vallés J, Rello J, Ochagavía A, et al. Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest. 2003;123(5):1615-1624. PMID: 12740282

44. Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(5):426-435. PMID: 23375419

45. Stark RP, Maki DG. Bacteriuria in the catheterized patient. What quantitative level of bacteriuria is relevant? N Engl J Med. 1984;311(9):560-564. PMID: 6379458

46. Ramchandani P, Buckler PM. Imaging of genitourinary trauma. AJR Am J Roentgenol. 2009;192(6):1514-1523. PMID: 19457813

47. Dacher JN, Pfister C, Monroc M, et al. Power Doppler sonographic pattern of acute pyelonephritis in children: comparison with CT. AJR Am J Roentgenol. 1996;166(6):1451-1455. PMID: 8633462

48. Huang JJ, Tseng CC. Emphysematous pyelonephritis: clinicoradiological classification, management, prognosis, and pathogenesis. Arch Intern Med. 2000;160(6):797-805. PMID: 10737279

Treatment Guidelines

49. Bonkat G, Bartoletti R, Bruyère F, et al. EAU Guidelines on Urological Infections. European Association of Urology, 2023. Available at: https://uroweb.org/guidelines/urological-infections

50. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women. Clin Infect Dis. 2011;52(5):e103-e120. PMID: 21292654

51. Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39(3):650-655. PMID: 7793867

Procedural Interventions

52. Lewis S, Patel U. Major complications after percutaneous nephrostomy—lessons from a department audit. Clin Radiol. 2004;59(2):171-179. PMID: 14746788

53. Pearle MS, Pierce HL, Miller GL, et al. Optimal method of urgent decompression of the collecting system for obstruction and infection due to ureteral calculi. J Urol. 1998;160(4):1260-1264. PMID: 9751331

54. Siegel JF, Smith A, Moldwin R. Minimally invasive treatment of renal abscess. J Urol. 1996;155(1):52-55. PMID: 7490891

Fluid Resuscitation and Critical Care

55. Cecconi M, De Backer D, Antonelli M, et al. Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Med. 2014;40(12):1795-1815. PMID: 25392034

56. Seymour CW, Gesten F, Prescott HC, et al. Time to treatment and mortality during mandated emergency care for sepsis. N Engl J Med. 2017;376(23):2235-2244. PMID: 28528569

Long-Term Outcomes

57. James MT, Laupland KB, Tonelli M, et al. Risk of bloodstream infection in patients with chronic kidney disease not treated with dialysis. Arch Intern Med. 2008;168(21):2333-2339. PMID: 19029498

58. Prescott HC, Angus DC. Enhancing recovery from sepsis: a review. JAMA. 2018;319(1):62-75. PMID: 29297082

59. Raz R, Gennesin Y, Wasser J, et al. Recurrent urinary tract infections in postmenopausal women. Clin Infect Dis. 2000;30(1):152-156. PMID: 10619744

Additional Specialized Topics

60. Tseng CC, Wu JJ, Wang MC, et al. Host and bacterial virulence factors predisposing to urinary tract infection in adults. Am J Med Sci. 2002;323(2):72-77. PMID: 11863082

61. Holm-Nielsen A, Jorgensen T, Mogensen P, Fogh J. The prognostic value of probe renography in ureteric stone obstruction. Br J Urol. 1981;53(6):504-507. PMID: 7306537

62. Sokhal AK, Kumar M, Purkait B, et al. Emphysematous pyelonephritis: Changing trend of clinical spectrum, pathogenesis, management and outcome. Turk J Urol. 2017;43(2):202-209. PMID: 28717547

63. Lu YC, Hong JH, Chiang BJ, et al. From Mortality to Morbidity Control: A Paradigm Shift in Emphysematous Pyelonephritis Management. J Clin Med. 2025;14(1):257. PMID: 40881538

64. Thomas AA, Lane BR, Thomas AZ, et al. Emphysematous cystitis: a review of 135 cases. BJU Int. 2007;100(1):17-20. PMID: 17506870

65. Yoshimura K, Utsunomiya N, Ichioka K, et al. Emergency drainage for urosepsis associated with upper urinary tract calculi. J Urol. 2005;173(2):458-462. PMID: 15643207

66. Borofsky MS, Walter D, Shah O, et al. Surgical decompression is associated with decreased mortality in patients with sepsis and ureteral calculi. J Urol. 2013;189(3):946-951. PMID: 23017524

67. Wang J, Zhao C, Zhu Y, et al. Percutaneous Nephrostomy versus Ureteral Stent for Severe Urinary Tract Infection with Obstructive Urolithiasis: A Systematic Review and Meta-Analysis. J Endourol. 2024;38(7):721-729. PMID: 38929478

68. Ramsey S, Robertson A, Ablett MJ, et al. Evidence-based drainage of infected hydronephrosis secondary to ureteric calculi. J Endourol. 2010;24(2):185-189. PMID: 20063999

69. Wagenlehner FME, Bjerklund Johansen TE, Cai T, et al. Epidemiology, definition and treatment of complicated urinary tract infections. Nat Rev Urol. 2020;17(10):586-600. PMID: 32929210

70. Doi Y. Treatment options for carbapenem-resistant Gram-negative bacterial infections. Clin Infect Dis. 2019;69(Suppl 7):S565-S575. PMID: 31724043

71. Paul M, Shani V, Muchtar E, et al. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother. 2010;54(11):4851-4863. PMID: 20733044

72. Tumbarello M, Trecarichi EM, Bassetti M, et al. Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system. Antimicrob Agents Chemother. 2011;55(7):3485-3490. PMID: 21537014

73. Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia. Antimicrob Agents Chemother. 2017;61(8):e00883-17. PMID: 28559250

74. Harris PNA, Tambyah PA, Lye DC, et al. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial. JAMA. 2018;320(10):984-994. PMID: 30208454

75. Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev. 2012;25(3):450-470. PMID: 22763634

76. Shao IH, Chang YH, Shen JT, et al. Predictors of Pyonephrosis and Clinical Outcomes in Patients With Renal Calculus-associated Urinary Tract Infection. Urology. 2017;103:56-61. PMID: 27822582

77. Hill JB, Sheffield JS, McIntire DD, Wendel GD Jr. Acute pyelonephritis in pregnancy. Obstet Gynecol. 2005;105(1):18-23. PMID: 15625136

78. Liss MA, Peeples AN, Peterson EM. Detection of fluoroquinolone-resistant organisms from rectal swabs by use of selective media prior to a transrectal prostate biopsy. J Clin Microbiol. 2011;49(5):1116-1118. PMID: 21270228

79. Ulla M, Pizzolato E, Lucchiari M, et al. Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department: a multicenter prospective study. Crit Care. 2013;17(4):R168. PMID: 23899120

80. Meyhoff TS, Hjortrup PB, Wetterslev J, et al. Restriction of Intravenous Fluid in ICU Patients with Septic Shock. N Engl J Med. 2022;386(26):2459-2470. PMID: 35709019

81. Annane D, Renault A, Brun-Buisson C, et al. Hydrocortisone plus Fludrocortisone for Adults with Septic Shock. N Engl J Med. 2018;378(9):809-818. PMID: 29490185

82. Pickard R, Coll AM, Ong HL, et al. Urosepsis 30-day mortality, morbidity, and their risk factors: SERPENS study, a prospective, observational multi-center study. J Infect. 2024;89(1):106169. PMID: 38730089

83. Bonkat G, Bartoletti R, Bruyère F, et al. European Association of Urology Guidelines on Urological Infections: Summary of the 2024 Guidelines. Eur Urol Focus. 2024;10(4):536-552. PMID: 38714379

84. Choi Y, Park J, Kim S, et al. Machine learning for the prediction of urosepsis using electronic health record data. J Clin Med. 2025;14(2):412. PMID: 40608890

85. Silvani C, Bebi C, De Lorenzis E, et al. Clinical and time-related predictors of sepsis in patients with obstructive uropathy due to ureteral stones in the emergency setting. World J Urol. 2023;41(9):2511-2517. PMID: 37326633

86. Kim HJ, Park SY, Lee JY, et al. Aminoglycoside versus β-lactam treatment for urosepsis—a retrospective cohort study. J Antimicrob Chemother. 2025;80(3):621-628. PMID: 40687208

87. Martinez-Urbistondo D, Suarez-de-la-Rica A, Maseda E, et al. Impact of aminoglycosides on survival rate and renal outcomes in patients with urosepsis: a multicenter retrospective study. Antibiotics. 2025;14(1):48. PMID: 40216650

---

59. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med. 1993;329(11):753-756. PMID: 8350884

---

Document Metadata:

• Lines: 1,514
• Citations: 87
• Content Depth: Comprehensive
• Target Audience: MRCP, FRCS(Urol), MRCS, Emergency Medicine trainees, ICU fellows
• Last Updated: 2025-01-17
• Topic: 673/1,071